A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas

Pancreatology

Volumn 15, Issue 4, 2015, Pages 397-404

  Xue, Aiqun ^a   Julovi, Sohel M ^a   Hugh, Thomas J ^a   Samra, Jaswinder S ^a   Wong, Matthew H F ^a   Gill, Anthony J ^a   Toon, Christopher W ^a   Smith, Ross C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adjuvant therapy; Gemcitabine; Immunohistochemistry; Pancreatic neoplasms; Subrenal fascia xenograft; Xenograft

Indexed keywords

CASPASE 3; CYTOKERATIN 7; GEMCITABINE; KI 67 ANTIGEN; ANTINEOPLASTIC ANTIBIOTIC; DEOXYCYTIDINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; VERY ELDERLY; ADJUVANT CHEMORADIOTHERAPY; ANALOGS AND DERIVATIVES; ANIMAL; FEMALE; KAPLAN MEIER METHOD; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE; PROCEDURES; SCID MOUSE; SUBRENAL CAPSULE ASSAY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; SUBRENAL CAPSULE ASSAY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937513437     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2015.04.008     Document Type: Article

References (43)

1. D.C. Ang, J. Shia, L.H. Tang, N. Katabi, and D.S. Klimstra The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater Am J Surg Pathol 38 10 2014 1371 1379
2. D.K. Chang, N.B. Jamieson, A.L. Johns, C.J. Scarlett, M. Pajic, A. Chou, and et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater J Clin Oncol 31 10 2013 1348 1356
3. S. Morini, G. Perrone, D. Borzomati, B. Vincenzi, C. Rabitti, D. Righi, and et al. Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival Pancreas 42 1 2013 60 66
4. J.P. Neoptolemos, D.D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham, D. Goldstein, and et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 10 2010 1073 1081
5. H. Oettle, and P. Neuhaus Adjuvant therapy in pancreatic cancer: a critical appraisal Drugs 67 16 2007 2293 2310
6. J.P. Neoptolemos, D. Cunningham, H. Friess, C. Bassi, D.D. Stocken, D.M. Tait, and et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives Ann Oncol 14 5 2003 675 692
7. J.P. Neoptolemos, M.J. Moore, T.F. Cox, J.W. Valle, D.H. Palmer, A.C. McDonald, and et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial JAMA 308 2 2012 147 156
8. B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, and et al. An in vivo platform for translational drug development in pancreatic cancer Clin Cancer Res 12 15 2006 4652 4661
9. I. Garrido-Laguna, M. Uson, N.V. Rajeshkumar, A.C. Tan, O.E. De, C. Karikari, and et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer Clin Cancer Res 17 17 2011 5793 5800
10. K. Jin, L. Teng, Y. Shen, K. He, Z. Xu, and G. Li Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review Clin Transl Oncol 12 7 2010 473 480
11. J.C. Cutz, J. Guan, J. Bayani, M. Yoshimoto, H. Xue, M. Sutcliffe, and et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes Clin Cancer Res 12 13 2006 4043 4054
12. D. Lin, J. Bayani, Y. Wang, M.D. Sadar, M. Yoshimoto, P.W. Gout, and et al. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor Prostate 70 15 2010 1636 1644
13. T. John, D. Kohler, M. Pintilie, N. Yanagawa, N.A. Pham, M. Li, and et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer Clin Cancer Res 17 1 2011 134 141
14. S. Pereira, P.A. Fernandes, and M.J. Ramos Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine J Comput Chem 25 10 2004 1286 1294
15. A. Andriulli, V. Festa, E. Botteri, M.R. Valvano, M. Koch, C. Bassi, and et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies Ann Surg Oncol 19 5 2012 1644 1662
16. S.B. Shi, M. Wang, Z.X. Niu, X.Y. Tang, and Q.Y. Liu Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer Pancreatology 12 6 2012 475 479
17. R. Klapdor, S. Klapdor, and M. Bahlo Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9 Anticancer Res 32 5 2012 2191 2197
18. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, and et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 15 2007 1960 1966
19. V. Berk, N. Ozdemir, M. Ozkan, S. Aksoy, N. Turan, A. Inal, and et al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer Hepatogastroenterology 59 120 2012 2635 2639
20. Y. Wang, M.P. Revelo, D. Sudilovsky, M. Cao, W.G. Chen, L. Goetz, and et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue Prostate 64 2 2005 149 159
21. X. Wu, J. Zhang, R. Zhen, J. Lv, L. Zheng, X. Su, and et al. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models J Transl Med 10 2012 180
22. N.A. Hamilton, T.C. Liu, A. Cavatiao, K. Mawad, L. Chen, S.S. Strasberg, and et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms Surgery 152 1 2012 107 113
23. R. Vang, A.M. Gown, T.S. Barry, D.T. Wheeler, A. Yemelyanova, J.D. Seidman, and et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases Am J Surg Pathol 30 9 2006 1130 1139
24. R. Marechal, J.B. Bachet, J.R. Mackey, C. Dalban, P. Demetter, K. Graham, and et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma Gastroenterology 143 3 2012 664 674
25. J.A. Joyce, and J.W. Pollard Microenvironmental regulation of metastasis Nat Rev Cancer 9 4 2009 239 252
26. C. Carmona-Fontaine, V. Bucci, L. Akkari, M. Deforet, J.A. Joyce, and J.B. Xavier Emergence of spatial structure in the tumor microenvironment due to the Warburg effect Proc Natl Acad Sci U S A 110 48 2013 19402 19407
27. N.E. Sharpless, and R.A. Depinho The mighty mouse: genetically engineered mouse models in cancer drug development Nat Rev Drug Discov 5 9 2006 741 754
28. T. Voskoglou-Nomikos, J.L. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res 9 11 2003 4227 4239
29. P.L. Garcia, L.N. Council, J.D. Christein, J.P. Arnoletti, M.J. Heslin, T.L. Gamblin, and et al. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma PLoS One 8 10 2013 e78183
30. C.H. Lee, C.L. Wu, Y.S. Tai, and A.L. Shiau Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy Mol Ther 11 5 2005 707 716
31. M.L. Rothenberg, M.J. Moore, M.C. Cripps, J.S. Andersen, R.K. Portenoy, H.A. Burris III, and et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 4 1996 347 353
32. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, and et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 18 2013 1691 1703
33. V. Vaccaro, I. Sperduti, and M. Milella FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 365 8 2011 768 769
34. R. Andersson, U. Aho, B.I. Nilsson, G.J. Peters, M. Pastor-Anglada, W. Rasch, and et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions Scand J Gastroenterol 44 7 2009 782 786
35. L.S. Hodge, M.E. Taub, and T.S. Tracy Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells Biochem Pharmacol 81 7 2011 950 956
36. L.S. Hodge, M.E. Taub, and T.S. Tracy The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase Drug Metab Dispos 39 11 2011 2013 2016
37. W. Greenhalf, P. Ghaneh, J.P. Neoptolemos, D.H. Palmer, T.F. Cox, R.F. Lamb, and et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial J Natl Cancer Inst 106 1 2014 djt347
38. E. Poplin, H. Wasan, L. Rolfe, M. Raponi, T. Ikdahl, I. Bondarenko, and et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity J Clin Oncol 31 35 2013 4453 4461
39. A. Neesse, P. Michl, K.K. Frese, C. Feig, N. Cook, M.A. Jacobetz, and et al. Stromal biology and therapy in pancreatic cancer Gut 60 6 2011 861 868
40. H. Kulbe, P. Chakravarty, D.A. Leinster, K.A. Charles, J. Kwong, R.G. Thompson, and et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment Cancer Res 72 1 2012 66 75
41. M. Tripathi, S. Billet, and N.A. Bhowmick Understanding the role of stromal fibroblasts in cancer progression Cell Adh Migr 6 3 2012 231 235
42. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, and et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 5933 2009 1457 1461
43. X. Dong, J. Guan, J.C. English, J. Flint, J. Yee, K. Evans, and et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy Clin Cancer Res 16 5 2010 1442 1451